CYCN (Cyclerion Therapeutics, Inc. Common Stock) Stock Analysis - News
Cyclerion Therapeutics, Inc. Common Stock (CYCN) is a publicly traded Healthcare sector company. As of May 21, 2026, CYCN trades at $3.02 with a market cap of $13.08M and a P/E ratio of -2.27. CYCN moved +4.33% today. Year to date, CYCN is +123.19%; over the trailing twelve months it is -6.21%. Its 52-week range spans $1.03 to $9.47. Rallies surfaces CYCN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in CYCN news today?
Investigation Challenges Cyclerion-Korsana Merger That Dilutes Shareholders to 1.5%: Cyclerion Therapeutics is proposing to merge with Korsana Biosciences, after which its shareholders would own approximately 1.5% of the combined company. An investigation has been launched into fiduciary breaches and deal terms that could limit superior offers while urging Cyclerion shareholders to review their legal rights.
Slate Path Capital LP sold 357.88K (~$555.11K) on Nov 21, 2024.
MCGUIRE TERRANCE sold 8 (~$27.16) on Aug 9, 2023.
MCGUIRE TERRANCE bought 92.83K (~$289.63K) on Jun 3, 2021.
CYCN Analyst Consensus
CYCN analyst coverage data. Average price target: $0.00.
Common questions about CYCN
What changed in CYCN news today?
Investigation Challenges Cyclerion-Korsana Merger That Dilutes Shareholders to 1.5%: Cyclerion Therapeutics is proposing to merge with Korsana Biosciences, after which its shareholders would own approximately 1.5% of the combined company. An investigation has been launched into fiduciary breaches and deal terms that could limit superior offers while urging Cyclerion shareholders to review their legal rights.
Does Rallies summarize CYCN news?
Yes. Rallies summarizes CYCN news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is CYCN research on Rallies investment advice?
No. Rallies provides research, data, and educational context for CYCN. It does not provide personalized investment advice.
